Terms: = Endocrine gland cancer AND SFRP4, Q6FHJ7, 6424, ENSG00000106483, frpHE, MGC26498, FRPHE, FRP-4
22 results:
1. Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and sfrp4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.
Turan H; Vitale SG; Kahramanoglu I; Della Corte L; Giampaolino P; Azemi A; Durmus S; Sal V; Tokgozoglu N; Bese T; Arvas M; Demirkiran F; Gelisgen R; Ilvan S; Uzun H
Arch Gynecol Obstet; 2022 Dec; 306(6):2105-2114. PubMed ID: 35461390
[TBL] [Abstract] [Full Text] [Related]
2. The miR-181a-sfrp4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian cancer.
Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
[TBL] [Abstract] [Full Text] [Related]
3. Identification of Differentially Expressed Genes Associated with Papillary Thyroid Carcinoma.
Cui H; Zhu M; Zhang J; Li W; Zou L; Wang Y
Comb Chem High Throughput Screen; 2020; 23(6):546-553. PubMed ID: 32238134
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic demethylation of sFRPs, with emphasis on sfrp4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.
Deshmukh A; Arfuso F; Newsholme P; Dharmarajan A
Int J Biochem Cell Biol; 2019 Apr; 109():23-32. PubMed ID: 30710752
[TBL] [Abstract] [Full Text] [Related]
5. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.
Nagase S; Ohta T; Takahashi F; Enomoto T;
J Obstet Gynaecol Res; 2019 Feb; 45(2):289-298. PubMed ID: 30426591
[TBL] [Abstract] [Full Text] [Related]
6. Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas.
Song W; Qian L; Jing G; Jie F; Xiaosong S; Chunhui L; Yangfang L; Guilin L; Gao H; Yazhuo Z
Mol Cell Endocrinol; 2018 Oct; 474():168-175. PubMed ID: 29555596
[TBL] [Abstract] [Full Text] [Related]
7. Finding Novel Anti-carcinomas Compounds by Targeting sfrp4 Through Molecular Modeling, Docking and Dynamic Simulation Studies.
Hassan M; Azhar M; Abbas Q; Raza H; Moustafa AA; Shahzadi S; Ashraf Z; Seo SY
Curr Comput Aided Drug Des; 2018; 14(2):160-173. PubMed ID: 29332600
[TBL] [Abstract] [Full Text] [Related]
8. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid cancer.
Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
[TBL] [Abstract] [Full Text] [Related]
9. Secreted Frizzled-related protein 4 (sfrp4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines.
Deshmukh A; Kumar S; Arfuso F; Newsholme P; Dharmarajan A
Sci Rep; 2017 May; 7(1):2256. PubMed ID: 28536422
[TBL] [Abstract] [Full Text] [Related]
10. Assessment of sfrp4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas.
Wu Y; Liu C; Yu S; Gao H; Li Z; Li C; Zhang Y
Oncol Rep; 2016 May; 35(5):2991-9. PubMed ID: 26935389
[TBL] [Abstract] [Full Text] [Related]
11. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy.
Estrella JS; Ma LT; Milton DR; Yao JC; Wang H; Rashid A; Broaddus RR
Pancreas; 2014 Oct; 43(7):996-1002. PubMed ID: 25058880
[TBL] [Abstract] [Full Text] [Related]
12. Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.
Wu Y; Bai J; Li Z; Wang F; Cao L; Liu C; Yu S; Yu G; Zhang Y
Pituitary; 2015 Jun; 18(3):335-42. PubMed ID: 24917361
[TBL] [Abstract] [Full Text] [Related]
13. Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours.
Szala A; Sawicki S; Swierzko AS; Szemraj J; Sniadecki M; Michalski M; Kaluzynski A; Lukasiewicz J; Maciejewska A; Wydra D; Kilpatrick DC; Matsushita M; Cedzynski M
Cancer Immunol Immunother; 2013 Aug; 62(8):1411-9. PubMed ID: 23744477
[TBL] [Abstract] [Full Text] [Related]
14. The Wnt gatekeeper sfrp4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract] [Full Text] [Related]
15. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
Fotopoulou C; Savvatis K; Kosian P; Braicu IE; Papanikolaou G; Pietzner K; Schmidt SC; Sehouli J
Br J Cancer; 2013 Jan; 108(1):32-8. PubMed ID: 23321509
[TBL] [Abstract] [Full Text] [Related]
16. Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
Saran U; Arfuso F; Zeps N; Dharmarajan A
BMC Cell Biol; 2012 Oct; 13():25. PubMed ID: 23039795
[TBL] [Abstract] [Full Text] [Related]
17. Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.
Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry JP; Guertler R; Hornung D; Mueller R; Fink DA; Hacker NF; Heinzelmann-Schwarz VA
PLoS One; 2012; 7(2):e31885. PubMed ID: 22363760
[TBL] [Abstract] [Full Text] [Related]
18. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.
Froeling FE; Feig C; Chelala C; Dobson R; Mein CE; Tuveson DA; Clevers H; Hart IR; Kocher HM
Gastroenterology; 2011 Oct; 141(4):1486-97, 1497.e1-14. PubMed ID: 21704588
[TBL] [Abstract] [Full Text] [Related]
19. The DNA methylome of benign and malignant parathyroid tumors.
Starker LF; Svedlund J; Udelsman R; Dralle H; Akerström G; Westin G; Lifton RP; Björklund P; Carling T
Genes Chromosomes Cancer; 2011 Sep; 50(9):735-45. PubMed ID: 21638518
[TBL] [Abstract] [Full Text] [Related]
20. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.
Schlumbrecht MP; Xie SS; Shipley GL; Urbauer DL; Broaddus RR
Mod Pathol; 2011 Mar; 24(3):453-62. PubMed ID: 21102415
[TBL] [Abstract] [Full Text] [Related]
[Next]
